Skip to main content
| News

Qnami secures investment of 4 million Swiss francs

17.05.2021

Qnami has raised a total of 4 million Swiss francs from investors after successfully closing a Series A financing round. The Basel Area-based startup has developed a quantum microscope technology that has since been patented as well as producing the first commercial quantum microscope.

The team of Qnami (img: Qnami)

Qnami has announced the successful closing of a Series A financing round in which the startup raised a total of 4 million Swiss francs in fresh capital. Qnami was founded in Basel in 2017 and is now based in Muttenz in the canton of Basel-Landschaft.

The financing round was led by the venture capitalists Runa Capital, which operates out of headquarters in both Silicon Valley and Europe, as well as SIT Capital, which is associated with the Schaffhausen Institute of Technology. The circle of investors included the venture capital companies Quantonation and Verve Ventures, which operate on a pan-European basis, in addition to the Bonn-based High-Tech Gründerfonds and the Cantonal Bank of Zurich.

With this fresh capital injection, Qnami intends to extend its patented quantum microscope technology into applications that will facilitate the design and production of quantum computers and spintronics devices. Furthermore, according to the press release issued by the company, the funds will be used to scale the market launch of the Qnami ProteusQ, the first commercial quantum microscope.

This device uses Qnami’s patented Quantilever diamond scanning probes. “We have gained good market traction with the launch of the ProteusQ and Quantilevers in the materials research setting”, explains Mathieu Munsch, co-founder and CEO of Qnami. “Top researchers already use Qnami’s technology to discover and describe the magnetic properties of new materials”, he adds.

According to Dmitry Galperin, General Partner at Runa Capital, the company is of the view that the technology could also be used for additional applications, including medical imaging and navigation, for example. Galperin is set to join the board of Qnami as a new member.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

South Korean pharma firms show interest in the Basel Area
Basel Area Business & Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.